Shanghai Serum Bio-Technology Co., Ltd.

SHSE:688163 Stock Report

Market Cap: CN¥1.9b

Shanghai Serum Bio-Technology Past Earnings Performance

Past criteria checks 1/6

Shanghai Serum Bio-Technology's earnings have been declining at an average annual rate of -11%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been declining at an average rate of 0.09% per year. Shanghai Serum Bio-Technology's return on equity is 4.6%, and it has net margins of 25.8%.

Key information

-11.0%

Earnings growth rate

-19.6%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate-0.09%
Return on equity4.6%
Net Margin25.8%
Next Earnings Update26 Apr 2025

Recent past performance updates

Recent updates

Earnings Not Telling The Story For Shanghai Serum Bio-Technology Co., Ltd. (SHSE:688163) After Shares Rise 44%

Oct 23
Earnings Not Telling The Story For Shanghai Serum Bio-Technology Co., Ltd. (SHSE:688163) After Shares Rise 44%

Optimistic Investors Push Shanghai Serum Bio-Technology Co., Ltd. (SHSE:688163) Shares Up 30% But Growth Is Lacking

Sep 03
Optimistic Investors Push Shanghai Serum Bio-Technology Co., Ltd. (SHSE:688163) Shares Up 30% But Growth Is Lacking

Revenue & Expenses Breakdown

How Shanghai Serum Bio-Technology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688163 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24197517824
30 Jun 24194447234
31 Mar 24192377733
31 Dec 23190397530
30 Sep 23191527228
30 Jun 23190617719
31 Mar 23173637315
31 Dec 22174647415
30 Sep 22190677520
30 Jun 22191687121
31 Mar 22211776725
31 Dec 21209766326
30 Sep 21194705823
31 Dec 20186635223
31 Dec 19188666019
31 Dec 18144425113
31 Dec 169629390
30 Sep 169229380
30 Jun 168929360
31 Mar 168322370
31 Dec 157614380
31 Dec 14607310

Quality Earnings: 688163 has high quality earnings.

Growing Profit Margin: 688163's current net profit margins (25.8%) are lower than last year (27.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688163's earnings have declined by 11% per year over the past 5 years.

Accelerating Growth: 688163's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 688163 had negative earnings growth (-2.5%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).


Return on Equity

High ROE: 688163's Return on Equity (4.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 15:12
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Serum Bio-Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution